Please Wait

Applying Filters...

Grow Your Pharma Business Digitally

Find Suppliers : API/FDF
- Search Our Integrated Database
Services
Excipients
Drugs in Dev.
News
Blog
Market Place
Login
Market Place

Information, Expiry & Status of FDA Orange Book Patents covering Abacavir Sulfate

Client Email

Product

Abacavir Sulfate
Abacavir
US Patents

EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

Contact Supplier

Bora Pharmaceuticals- Making success more certain.

Contact Supplier

Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

Contact Supplier

Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.

Contact Supplier

Axplora- The partner of choice for complex APIs.

Contact Supplier

Fareva is a one-stop-shop for API/HPAPI, OSD & Sterile products, is USFDA, EMA and PMDA-inspected and has multiple NDA & ANDA filings.

Contact Supplier

Abacavir Sulfate

ACCESS ALL DATA, CHEMISTRY

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

30 API Suppliers, 12 USDMF, 10 CEP/COS, 1 JDMF, 11 EU WC, 3 KDMF, 14 NDC API, 15 Listed Suppliers, $ API Reference Price

30 API Suppliers
12 USDMF
10 CEP/COS
1 JDMF
11 EU WC
3 KDMF
14 NDC API
15 Listed Suppliers
$ API Reference Price

PRICE INFORMATION

API Reference Price, API Exports, API Imports, FDF Exports, FDF Imports

API Reference Price
API Exports
API Imports
FDF Exports
FDF Imports

INTERMEDIATES

1 API Suppliers

1 API Suppliers

FINISHED DOSAGE FORMULATIONS

66 FDF Dossiers, 34 FDA Orange Book, 8 Europe, 11 Canada, 10 South Africa, 3 Listed Dossiers

66 FDF Dossiers
34 FDA Orange Book
8 Europe
11 Canada
10 South Africa
3 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET;ORAL - EQ 600MG BASE;EQ 50MG BASE;300MG, TABLET;ORAL - EQ 300MG BASE, SOLUTION;ORAL - EQ 20MG BASE/ML, TABLET;ORAL - EQ 600MG BASE;300MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET;ORAL - EQ 600MG BASE;EQ 50MG BASE;300MG
TABLET;ORAL - EQ 300MG BASE
SOLUTION;ORAL - EQ 20MG BASE/ML
TABLET;ORAL - EQ 600MG BASE;300MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

RELATED EXCIPIENT COMPANIES

3 Rochem International Inc, 17 SPI Pharma, 2 Seqens, 5 DKSH, 2 Jai Radhe Sales, 1 Boai NKY Pharmaceuticals Ltd, 13 Gangwal Healthcare, 4 Nanjing Well Pharmaceutical, 1 Pfanstiehl, 1 ACG Worldwide, 8 Actylis, 1 Aeon Procare, 9 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 22 BASF, 1 Clariant, 10 Corel Pharma Chem, 4 DFE Pharma, 2 Finar, 11 Gangwal Chemicals, 7 Ideal Cures Pvt Ltd, 5 Ingredion Pharma Solutions, 19 Kerry, 3 Kima Chemical, 6 Lonza Capsugel, 11 Microlex e.U, 1 Nanjing Bold Chemical, 2 Nomisma Healthcare, 3 Novo Excipients, 3 Pharmatrans-Sanaq, 5 Pluviaendo, 4 Prachin Chemical, 1 Qianhao Chemical (Hebei) Co., Ltd, 1 Qualicaps, 29 Roquette, 13 Seppic, 6 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 2 Shijiazhuang Huaxu Pharmaceutical, 11 Sigachi Industries, 2 The Dow Chemical Company, 1 Ulanqab Kema New Material, 1 Valens Pharmachem, 4 Vasa Pharmachem, 1 Zhejiang Huakang Pharmaceutical

EXCIPIENTS BY APPLICATIONS

65 Fillers, Diluents & Binders, 53 Coating Systems & Additives, 36 Direct Compression, 33 Controlled & Modified Release, 31 Disintegrants & Superdisintegrants, 24 Thickeners and Stabilizers, 24 Solubilizers, 21 Film Formers & Plasticizers, 20 Granulation, 20 Taste Masking, 18 Parenteral, 16 Chewable & Orodispersible Aids, 16 Co-Processed Excipients, 15 Topical, 14 Lubricants & Glidants, 8 Emulsifying Agents, 7 API Stability Enhancers, 5 Rheology Modifiers, 5 Empty Capsules, 5 Coloring Agents, 4 Vegetarian Capsules, 3 Surfactant & Foaming Agents, 1 Soft Gelatin

65 Fillers, Diluents & Binders
53 Coating Systems & Additives
36 Direct Compression
33 Controlled & Modified Release
31 Disintegrants & Superdisintegrants
24 Thickeners and Stabilizers
24 Solubilizers
21 Film Formers & Plasticizers
20 Granulation
20 Taste Masking
18 Parenteral
16 Chewable & Orodispersible Aids
16 Co-Processed Excipients
15 Topical
14 Lubricants & Glidants
8 Emulsifying Agents
7 API Stability Enhancers
5 Rheology Modifiers
5 Empty Capsules
5 Coloring Agents
4 Vegetarian Capsules
3 Surfactant & Foaming Agents
1 Soft Gelatin

DIGITAL CONTENT

1 DATA COMPILATION #PharmaFlow, 23 NEWS #PharmaBuzz

1 DATA COMPILATION #PharmaFlow
23 NEWS #PharmaBuzz

GLOBAL SALES INFORMATION

3 US Medicaid Prescriptions, 8 Finished Drug Prices, 5 Annual Reports

3 US Medicaid Prescriptions
8 Finished Drug Prices
5 Annual Reports

MARKET PLACE

1 APIs, 2 FDF Dossiers

1 APIs
2 FDF Dossiers

PATENTS & EXCLUSIVITIES

8 US Patents, 4 US Exclusivities, 8 Health Canada Patents

8 US Patents
4 US Exclusivities
8 Health Canada Patents

REF. STANDARDS & IMPURITIES

3 EDQM, 2 USP, 2 Others

3 EDQM
2 USP
2 Others

$ API Ref.Price (USD/KG) : 345 Xls

Filters

Reset all filters

Filters

FILTER :

filter Applicant Reset all filters

8 All

01 8VIIV HLTHCARE

filter Patent Number Reset all filters

8 All

01 28129385

02 28129385*PED

03 29242986

04 29242986*PED

filter API Patent Reset all filters

8 All

01 4Y

02 4Blank

filter FDF Patent Reset all filters

8 All

01 4Y

02 4Blank

filter Expiration Date Reset all filters

8 All

01 22027-10-05

02 22028-04-05

03 22029-12-08

04 22030-06-08

US Patents
US Exclusivities
Health Canada Patents

Product Main Page

01

VIIV HLTHCARE

ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE

FNCE 2024

Not Confirmed

VIIV HLTHCARE

FNCE 2024

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2029-12-08

ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE

US Patent Number : 9242986

Drug Substance Claim : Y

Drug Product Claim : Y

Application Number : 205551

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2029-12-08

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

02

VIIV HLTHCARE

ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE

FNCE 2024

Not Confirmed

VIIV HLTHCARE

FNCE 2024

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2027-10-05

ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE

US Patent Number : 8129385

Drug Substance Claim : Y

Drug Product Claim : Y

Application Number : 205551

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2027-10-05

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

03

VIIV HLTHCARE

ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE

FNCE 2024

Not Confirmed

VIIV HLTHCARE

FNCE 2024

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2029-12-08

ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE

US Patent Number : 9242986

Drug Substance Claim : Y

Drug Product Claim : Y

Application Number : 215413

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2029-12-08

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

04

VIIV HLTHCARE

ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE

FNCE 2024

Not Confirmed

VIIV HLTHCARE

FNCE 2024

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2027-10-05

ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE

US Patent Number : 8129385

Drug Substance Claim : Y

Drug Product Claim : Y

Application Number : 215413

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2027-10-05

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

05

VIIV HLTHCARE

ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE

FNCE 2024

Not Confirmed

VIIV HLTHCARE

FNCE 2024

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2028-04-05

ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE

US Patent Number : 8129385*PED

Drug Substance Claim :

Drug Product Claim :

Application Number : 205551

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2028-04-05

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

06

VIIV HLTHCARE

ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE

FNCE 2024

Not Confirmed

VIIV HLTHCARE

FNCE 2024

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2030-06-08

ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE

US Patent Number : 9242986*PED

Drug Substance Claim :

Drug Product Claim :

Application Number : 205551

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2030-06-08

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

07

VIIV HLTHCARE

ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE

FNCE 2024

Not Confirmed

VIIV HLTHCARE

FNCE 2024

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2030-06-08

ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE

US Patent Number : 9242986*PED

Drug Substance Claim :

Drug Product Claim :

Application Number : 215413

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2030-06-08

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

08

VIIV HLTHCARE

ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE

FNCE 2024

Not Confirmed

VIIV HLTHCARE

FNCE 2024

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2028-04-05

ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE

US Patent Number : 8129385*PED

Drug Substance Claim :

Drug Product Claim :

Application Number : 215413

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2028-04-05

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

Contact us
to update this info

Privacy policy
Terms and conditions
Disclaimers
LOOKING FOR A SUPPLIER?